Long acting GLP-1 receptor agonist (injectable)
Ecnoglutide 1.2 mg injection once weekly
ECNO_SC_1p2MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.79 (-2.52 to -0.94) | 0.88 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 5.48 (0.19 to 171) | 0.19 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 5.26 (0.18 to 173) | 0.28 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.25 (1.16 to 32.40) | 0.28 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.95 (0.45 to 104) | 0.31 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.86 (1.12 to 28.25) | 0.16 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.42 (0.26 to 8.65) | 0.52 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.83 (0.05 to 13.51) | 0.47 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.64 (0.01 to 50.05) | 0.58 |